Parkinson's disease, multiple sclerosis, traumatic brain injury, and spinal cord injury. High-stakes conditions with promising early research — but families need honest information.
Critical Disclaimer: Neurological stem cell therapy is an active research area with promising but inconclusive evidence. No stem cell treatment has been approved by the FDA or INVIMA specifically for neurological conditions. This page presents the current state of research honestly to help families make informed decisions.
Neurological conditions — Parkinson's disease, multiple sclerosis, stroke, traumatic brain injury, and spinal cord injury — represent some of the most devastating diagnoses a patient can receive. Conventional treatments primarily manage symptoms rather than addressing the underlying damage to neural tissue.
This is why stem cell therapy generates so much hope: the idea that damaged neurons, myelin sheaths, or neural pathways could be repaired or supported by transplanted cells is extraordinarily compelling. And the science is genuinely moving forward. A 2025 review identified 781 registered clinical trials testing MSC-based strategies for neurological disorders, with 287 completed and 44 reporting results.
But hope must be balanced with reality. Most neurological stem cell trials are Phase I–II (safety and early efficacy), not large-scale Phase III trials that would establish definitive proof of benefit. Colombian clinics offering these treatments are providing protocols that are biologically plausible and appear safe, but that have not been proven to produce consistent, reliable neurological improvement.
Parkinson's disease has the most exciting recent data: two 2025 clinical trials published in Nature demonstrated that transplanting dopamine-releasing neurons derived from stem cells into the brain is safe, with early evidence of symptom improvement in some patients. The FDA approved a Phase 3 trial based on these results. For MS, MSC therapy has shown improvements in motor, sensory, and cognitive functions in multiple clinical trials. For TBI and spinal cord injury, results are encouraging but highly variable. Across all neurological conditions, safety profiles have been generally favorable.
The most actively researched neurological application. MSC therapy aims to reduce neuroinflammation and provide neurotrophic support. More advanced approaches (iPSC-derived dopamine neurons) are in clinical trials but are not yet available commercially. Colombian clinics offer MSC-based protocols.
Promising research • $15,000–$25,000MSCs may help modulate the overactive immune system that attacks myelin in MS. Clinical trials have demonstrated improvements in disability scores, with some patients experiencing reduced relapse rates. This is among the better-studied neurological applications.
Moderate evidence • $12,000–$20,000TBI damages neural tissue through both the initial impact and secondary inflammation. MSC therapy targets the inflammatory cascade. Results are highly variable — some patients report meaningful improvements, while others see limited change. Timing relative to injury matters significantly.
Early evidence • $12,000–$22,000One of the most challenging neurological applications. MSCs may support partial neural recovery through anti-inflammatory and neurotrophic mechanisms. Incomplete injuries (some preserved function) respond better than complete injuries. Outcomes vary widely.
Early evidence • $15,000–$25,000Post-stroke stem cell therapy aims to support neural repair during the recovery window. Some trials show improvements in motor function and independence when treatment is initiated within months of the stroke event.
Early evidence • $10,000–$20,000Amyotrophic lateral sclerosis, cerebral palsy, and other degenerative conditions have been explored in clinical trials. Evidence is very early-stage, and expectations should be carefully managed. Some clinics offer compassionate-use protocols.
Very early evidence • $15,000–$25,000| Treatment | Colombia | US Price (where available) | Savings |
|---|---|---|---|
| Parkinson's MSC protocol | $15,000–$25,000 | $40,000–$60,000+ | 55–65% |
| MS MSC therapy | $12,000–$20,000 | $30,000–$50,000 | 55–65% |
| TBI protocol | $12,000–$22,000 | $35,000–$55,000 | 55–65% |
| Spinal cord injury protocol | $15,000–$25,000 | $45,000–$70,000 | 60–65% |
Prices estimated as of 2026. Neurological protocols are the most expensive stem cell treatments due to complexity, cell counts required, and multi-day monitoring. US pricing is limited because most US clinics do not offer these protocols outside of clinical trials.
If you are researching neurological stem cell therapy for a loved one, you are likely in a difficult situation. Conventional medicine may have offered limited options, and the promise of regenerative medicine is understandably compelling.
We want to be direct: no one should travel to Colombia expecting a cure for Parkinson's, MS, or spinal cord injury from stem cell therapy. The goal of current protocols is more modest — potential slowing of progression, reduction of inflammation, and incremental improvements in function or quality of life.
Some patients and families report meaningful improvements that justify the investment. Others do not see significant change. Without large-scale controlled trials, it is impossible to predict who will benefit.
Before committing to any neurological stem cell treatment, ask: What is your clinic's specific outcome data for my condition? What cell type, dose, and delivery method do you use? Do you have published results or a clinical trial registry? What is the realistic range of outcomes your patients experience? What monitoring and follow-up do you provide? A responsible clinic will answer all of these questions transparently.
For help navigating this complex landscape and connecting with clinics that are transparent about neurological protocols, reach out for a free consultation.
Tell us about your condition and what you have tried so far. We will help you understand what Colombian clinics can realistically offer for your situation.
Get Free Consultation